Exclusive: Amneal running out of hydroxychloroquine raw material due to Finnish restrictions

Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker's chief executives.